Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Gynecologic Oncology|January 11, 2021
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 womenIan S Hagemann, Wei Deng, Richard J Zaino, et al.
Gynecologic Oncology|December 14, 2021
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology studyUrsula A Matulonis, Helen Q Huang, Virginia L Filiaci, et al.
Gynecologic Oncology|March 26, 2017
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyDanielle A Jandial, William E Brady, Stephen B Howell, et al.
The New England Journal of Medicine|June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial CancerDaniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Gynecologic Oncology|September 12, 2024
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14Jubilee Brown, Austin Miller, Laura L Holman, et al.
Gynecologic Oncology|July 6, 2024
A toolkit for a modern gynecologic oncology tissue bankOlivia Graham, Jeimmy Rodriguez, Rachel Abbott, et al.
Molecular Cancer Therapeutics|May 19, 2022
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell GlycolysisShaina F Bruce, Kevin Cho, Hollie Noia, et al.
Cancer Research|December 7, 2007
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancerZhengyan Zhang, Ingrid Borecki, Loan Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)David S Miller, Virginia L Filiaci, Robert S Mannel, et al.
Molecular Cancer Research : MCR|October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication StressMary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
Pageof 25